ArticleThe journal of pathology. Clinical research2026
The molecular landscape of nodular fasciitis: novel USP6 fusions, genomic stability, and an exploratory clinicopathological model - a 20-year retrospective study.
Article in The journal of pathology. Clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nodular fasciitis (NF) is a benign myofibroblastic neoplasm characterized by rapid growth and recurrent USP6 rearrangements. Despite its benign nature, NF may exhibit worrisome histologic or clinical features that mimic sarcoma, posing diagnostic challenges. The relationship between molecular diversity and morphologic heterogeneity remains incompletely understood. We retrospectively analyzed 283 NF cases diagnosed between 2000 and 2024 at a tertiary referral center. Molecular testing for USP6 rearrangements was performed in 44 cases using targeted RNA sequencing. Histologic features, clinical parameters, and fusion partner distribution were evaluated, with emphasis on lesions showing infiltrative or worrisome morphology. Selected cases underwent additional genomic profiling, including hybrid-capture DNA sequencing and copy-number analysis. Among 44 molecularly confirmed cases, 18 distinct USP6 fusion partners were identified. The most frequent fusion was MYH9::USP6 (40.9%), followed by COL1A1::USP6, MIR22HG::USP6, and RRBP1::USP6. Rare and previously unreported fusions, including CLK1::USP6 and FOSL2::USP6, further expanded the molecular spectrum. Two cases with infiltrative, aggressive-appearing morphology showed no additional pathogenic alterations and a genomically stable profile. Based on these findings, we propose an exploratory, hypothesis-generating framework to summarize the observed clinicopathological spectrum of NF. NF demonstrates substantial molecular heterogeneity but retains a genetically simple and largely benign biological behavior. Even lesions with alarming morphology appear genomically stable and clinically indolent. The proposed framework may facilitate diagnostic interpretation and provide a conceptual framework for future studies but requires validation before any biological or clinical implications can be inferred.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.